Recombinant T Cell Receptor Ligand Treats Experimental Stroke

Abstract

These data are the first to demonstrate successful treatment of experimental stroke using a neuroantigen-specific immunomodulatory agent administered after ischemia, suggesting therapeutic potential in human stroke.